VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity was originally published by The Motley Fool ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Ken's career includes key leadership roles in organizations such as the Ontario Government, Victoria University (Toronto), Brock University, Cystic Fibrosis Canada, and Vertex Pharmaceuticals. His ...

A Bicester School Sixth Form student "rediscovered her love of learning" earlier this year following a summer internship at ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Andrew Fein has given his Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ potential success with its drug candidate suzetrigine. The drug’s mechanism of action, which ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

As Vertex Pharmaceuticals Inc. heads toward the end of 2024, the Boston drugmaker is gearing up for two potential drug ...